How Can Gastric Cancer Molecular Profiling Guide Future Therapies?

Research output: Contribution to journalReview articlepeer-review


Gastric cancer is the third greatest global cause of cancer-related deaths. Despite its high prevalence, only recently have comprehensive genomic surveys shed light on its molecular alterations. As surgery is the only curative treatment strategy and chemotherapy has shown limited efficacy, new treatments are urgently needed. Many molecular therapies for gastric cancer have entered clinical trials but–apart from Trastuzumab and Ramucirumab–all have failed. We analyze the current knowledge of the genetic ‘landscape’ of gastric cancers, elaborating on novel, preclinical approaches. We posit that this knowledge lays the basis for identifying bona fide molecular targets and developing solid therapeutic approaches, requiring accurate patient selection and taking advantage of preclinical models to assist clinical development of novel combination strategies.

Original languageEnglish
Pages (from-to)534-544
Number of pages11
JournalTrends in Molecular Medicine
Issue number7
Publication statusPublished - Jul 1 2016


  • gastric cancer
  • HER2
  • targeted therapies
  • tyrosine kinase receptors

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine


Dive into the research topics of 'How Can Gastric Cancer Molecular Profiling Guide Future Therapies?'. Together they form a unique fingerprint.

Cite this